Patents by Inventor Serge Masson
Serge Masson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230366894Abstract: The present invention relates to a method for diagnosing atrial fibrillation in a subject, said method comprising the steps of a) determining the amount of total NT-proBNP in sample from the subject, b) determining the amount of unglycosylated NT-proBNP in a sample from the subject, c) calculating a score of the amounts determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing atrial fibrillation in a subject.Type: ApplicationFiled: September 30, 2021Publication date: November 16, 2023Inventors: Johann Karl, Peter Kastner, Roberto Latini, Serge Masson, Jennifer Marie Theresia Anna Meessen, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen, André Ziegler
-
Patent number: 11644472Abstract: A method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject is described. Also described is a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Also described are devices adapted to carry out the method of the present disclosure.Type: GrantFiled: December 12, 2018Date of Patent: May 9, 2023Assignee: Roche Diagnostics Operations, Inc.Inventors: Herbert Andres, Dirk Block, Johann Karl, Peter Kastner, Ursula-Henrike Wienhues-Thelen, Roberto Latini, Serge Masson, Andre Ziegler, Edelgard Kaiser, Stefan Palme, Markus Thomas, Simona Barlera
-
Publication number: 20230062697Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.Type: ApplicationFiled: August 24, 2022Publication date: March 2, 2023Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
-
Publication number: 20220412991Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.Type: ApplicationFiled: August 19, 2022Publication date: December 29, 2022Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg
-
Patent number: 11454634Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.Type: GrantFiled: March 5, 2018Date of Patent: September 27, 2022Assignee: Roche Diagnostics Operations, Inc.Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg
-
Publication number: 20220229075Abstract: The present invention relates to a method for differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) in a subject suffering from heart failure, said method comprising the steps of determining the amounts of IGFBP7 (Insulin-like growth factor-binding protein 7), of a BNP-type peptide, and optionally of CRP (C-reactive protein) in a sample from the subject, calculating (i) a ratio of the amount of IGFBP7 and the amount of the BNP-peptide or (ii) a ratio of the sum of the amounts of IGFBP7 and CRP and the amount of the BNP-type peptide, comparing the ratio calculated with a reference ratio, and differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The present invention further concerns a method for the diagnosis of HFpEF.Type: ApplicationFiled: May 22, 2020Publication date: July 21, 2022Inventors: Kai HABBEN, Vinzent ROLNY, Anika MANG, Ursula-Henrike WIENHUES-THELEN, Serge MASSON
-
Publication number: 20200371114Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.Type: ApplicationFiled: December 19, 2019Publication date: November 26, 2020Applicant: Roche Diagnostics Operations, Inc.Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
-
Patent number: 10557858Abstract: Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.Type: GrantFiled: April 28, 2017Date of Patent: February 11, 2020Assignee: Roche Diagnostics Operations, Inc.Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
-
Publication number: 20190353666Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.Type: ApplicationFiled: December 12, 2018Publication date: November 21, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Herbert Andres, Dirk Block, Johann Karl, Peter Kastner, Ursula-Henrike Wienhues-Thelen, Roberto Latini, Serge Masson, Andre Ziegler, Edelgard Kaiser, Stefan Palme, Markus Thomas, Simona Barlera
-
Publication number: 20190162737Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.Type: ApplicationFiled: February 1, 2019Publication date: May 30, 2019Applicants: Roche Diagnostics Operations, Inc., Maastricht University Medical CenterInventors: Johann Karl, Peter Kastner, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Andre Ziegler, Manuel Dietrich, Ulrich Schotten, Vinzent Rolny
-
Publication number: 20180196067Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.Type: ApplicationFiled: March 5, 2018Publication date: July 12, 2018Applicant: Roche Diagnostics Operations, Inc.Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg
-
Publication number: 20170227552Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.Type: ApplicationFiled: April 28, 2017Publication date: August 10, 2017Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
-
Publication number: 20170074892Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.Type: ApplicationFiled: November 23, 2016Publication date: March 16, 2017Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
-
Publication number: 20150233946Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.Type: ApplicationFiled: May 6, 2015Publication date: August 20, 2015Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
-
Publication number: 20150185230Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.Type: ApplicationFiled: March 11, 2015Publication date: July 2, 2015Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg
-
Patent number: 6729948Abstract: The present invention relates to a method and apparatus for rectifying cylindrical articles, in particular nuclear fuel pellets. In said method, in characteristic manner, the dust generated by the rectification by a working grind wheel acting on said pellets remains confined and practically all of it is entrained beside said working grind wheel so as to be taken away by forced suction.Type: GrantFiled: June 4, 2002Date of Patent: May 4, 2004Assignee: Compagnie Generale des Matieres NucleaiesInventors: Pascal Engelvin, Michel Marchand, Serge Masson
-
Publication number: 20030146312Abstract: The subject of the present invention is:Type: ApplicationFiled: June 18, 2002Publication date: August 7, 2003Applicant: Compagnie Generale Des Matieres NucleairesInventors: Serge Masson, Pierre Martinet, Jean-Marc Ligney, Benoit Duval
-
Publication number: 20020193057Abstract: The present invention relates to a method and apparatus for rectifying cylindrical articles, in particular nuclear fuel pellets. In said method, in characteristic manner, the dust generated by the rectification by a working grind wheel acting on said pellets remains confined and practically all of it is entrained beside said working grind wheel so as to be taken away by forced suction.Type: ApplicationFiled: June 4, 2002Publication date: December 19, 2002Applicant: Compagnie Generale Des Matieres NucleairesInventors: Pascal Engelvin, Michel Marchand, Serge Masson
-
Patent number: 4446815Abstract: The apparatus comprises a nozzle (2) having three converging tuyeres (3, 4, 5) which project the reagents (SnCl.sub.4 and H.sub.2 O) in the gaseous phase onto the substrate to be plated. Deflector members (6a, 6b), which are adapted to channel the gases between themselves and the substrate, extend on either side of the nozzle (2). The surface (51) of the deflector member (12) which extends in the opposite direction to the direction of movement of the substrate with respect to the nozzle is parallel to the substrate, and the edge (53) which it forms at an acute angle with the extended external wall (5b) of the third tuyere (5) is transversely offset in the direction of the said movement with respect to the axial median plane of the tuyere (3). On the other hand, the surface (52) of the second deflector member (5a) forms a blunt edge (54) with the corresponding longitudinal wall (4b) of the second tuyere.Type: GrantFiled: December 14, 1982Date of Patent: May 8, 1984Assignee: Societa Italiana Vetro SIV SpAInventors: Reinhard Kalbskopf, Otto Baumberger, Serge Masson